According to BCC Research Report, the global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a compound annual growth rate (CAGR) of 18.0 percent for the period of 2017-2022. As the opioid epidemic in the United States continues unabated, doctors in many specialties are trying new ways to treat acute and chronic pain. More and more primary care doctors are begging to utilize non-opioid treatment and therapies more often by first considering non-opioid medications.
Non-opioid medications are proving to be effective as a first-line treatment, including acetaminophen, NSAIDs, and drugs tailored for neuropathic, or nerve-related, pain. BCC Research analyst and report author Melissa Elder said, “A concentrated effort is needed to educate providers and payers about the value and potential cost savings of effective pain management. As the industry continues to focus on cost-effective pain management, finding treatments that have minimal side effects and control pain effectively will be the most valuable to providers and patients. Many studies have shown good pain management reduces complications and hospital lengths of stay, with significant savings that far exceed the cost of the technology or drugs used.”
(Source: Report Linker)
Filed Under: Drug Discovery